Prostate Cancer

“So many patients with prostate cancer qualify for genetic testing, but it's currently underutilized,” says Stacy Loeb, MD, MSc.

“The benefits can be reaped by the vast majority of patients and because we're really undertreating these patients, we need to make a conscious effort to overcome whatever barriers are facing us,” says Alicia Morgans, MD, MPH.

“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.

“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” the authors wrote.

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.

Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.

Stephen J. Freedland, MD, presents the case of a 67-year-old man with metastatic prostate cancer and give his initial impression.

In response to the findings, The American Cancer Society is launching IMPACT, an initiative aimed at reducing prostate cancer mortality.

“We don’t want to subject patients to a therapeutic strategy that they are unlikely to benefit from,” says Atish D. Choudhury, MD, PhD.

The environmental footprint of prostate MRI and prostate biopsy is similar to a round-trip flight from London to Paris, according to the authors.

In this interview, Arvin K. George, MD, gives an overview of the current state of focal therapy and also discusses 2 clinical trials evaluating new technologies in the space.

"Even though most of the end points had been negative and found no benefit, I think there are a couple of findings that we've learned in 2022 that surprised me," says Mark A. Moyad, MD, MPH.

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”

"[Low-grade prostate cancer] is a really interesting field right now," says Kevin Shee, MD, PhD.

Ashley E. Ross, MD, PhD, provides an overview of his institution’s new protocol for this subset of patients.

“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.

The TAVT-45 formulation of abiraterone acetate was created for patients with dysphagia, who would have difficulty swallowing a tablet.

Based on current studies and anecdotal evidence, many of today’s urologists think it’s relatively safe to administer testosterone replacement in hypogonadal men on active surveillance or in those who have been treated with prostatectomy or cryosurgery. But these men should be closely monitored, they stress.

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

"It’s apparent that reducing overdiagnosis alone may not necessarily reduce over treatment, and that separate and specific focus on prevention of over treatment is still needed," Badar M. Mian, MD, writes.

“The number of views, viewer engagement, and the length of the video didn't have an impact on the score at all when we did our analysis,” says Daniel Bockelman.

“It's important to put out information that's both accurate and helps to supplement in-office decision making in an outpatient setting,” says Daniel Bockelman.